Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
SOPHiA GENETICS (Nasdaq: SOPH) has announced an extension of its partnership with Institut Paoli Calmettes (IPC) to enhance automated testing for solid tumors, including lung, breast, and ovarian cancers. This collaboration, which started in 2016, focuses on optimizing cancer management through genomic profiling, thereby minimizing sequencing costs and reporting times. IPC, recognized for managing hereditary cancers and hematologic malignancies, employs 1,800 personnel dedicated to comprehensive cancer care. The partnership aims to improve diagnostic accuracy and treatment predictions for cancer patients.
SOPHiA GENETICS (Nasdaq: SOPH) appointed Ken Freedman as Chief Revenue Officer on January 26, 2022. Freedman brings over 25 years of experience in sales and marketing from his previous role as Executive VP of Sales at Naviga, where he successfully grew revenue streams in North America and Latin America. His expertise is expected to bolster SOPHiA's expansion plans following a successful IPO. CEO Jurgi Camblong emphasized Freedman's motivational leadership and belief in data-driven approaches to enhance patient outcomes.
SOPHiA GENETICS (NASDAQ: SOPH) announced significant progress in its DEEP-Lung-IV clinical study, with 12 sites across 5 countries participating. The study aims to identify predictive biomarkers for non-small cell lung cancer (NSCLC) immunotherapy responses, addressing the limitations of the current PD-L1 biomarker. The initiative targets enrollment of 4,000 patients, with over 2,000 expected from initial sites. CEO Dr. Jurgi Camblong expressed optimism about the study's momentum and its potential impact in clinical settings.
SOPHiA GENETICS (Nasdaq: SOPH) announced significant leadership changes, hiring Peter Casasanto as Chief BioPharma Officer and Abhimanyu Verma as Chief Technology Officer. This move aligns with their strategy to enhance their footprint in the BioPharma sector. CEO Jurgi Camblong emphasized the importance of innovation in data-driven medicine. Peter brings over 15 years of life sciences experience, while Abhi has over 17 years in technology and data-driven drug development. Their expertise aims to support the company’s goal of advancing healthcare through comprehensive data insights.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that CEO Dr. Jurgi Camblong and CFO Ross Muken will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. ET. The presentation will be accessible live and archived on their website. SOPHiA GENETICS is focused on data-driven medicine and operates the SOPHiA DDM™ Platform used by over 780 institutions worldwide.
SOPHiA GENETICS has launched the DEEP-Lung-IV clinical study (NCT04994795) to analyze multimodal real-world data for predicting immunotherapy responses in 4,000 patients with stage IV non-small cell lung cancer (NSCLC). This large-scale study encompasses approximately 30 sites across North America, Europe, and Latin America. The initiative seeks to identify new predictive biomarkers, enhancing patient stratification and treatment decisions. The company aims to generate actionable insights to improve clinical outcomes in NSCLC patients, leveraging its proprietary SOPHiA DDM™ Platform.
SOPHiA GENETICS (Nasdaq: SOPH) will host a joint symposium with GE Healthcare on December 1, 2021, at the RSNA Annual Meeting in Chicago. The event, focused on advancing data-driven medicine, will explore multimodal digital health data integration using AI-powered analytics. This follows a recent Master Alliance Agreement between the two companies, aiming to enhance collaboration in healthcare solutions, particularly in digital oncology and radiogenomics. The partnership is expected to accelerate the adoption of SOPHiA's platform, enhancing healthcare delivery for cancer patients worldwide.
Balderton Capital has launched its largest-ever fund of $600m to support early-stage startups, complementing its Growth fund raised earlier this year. The firm is now deploying over $1.2bn across Europe, leveraging its extensive investment team of 25 experts. Balderton has made close to 300 investments, including 20 new startups in various sectors. Its portfolio companies have raised over $6bn in follow-on funding this year, highlighting a successful track record with 13 companies reaching unicorn status.
SOPHiA GENETICS (Nasdaq: SOPH) reported a robust 45% year-over-year revenue growth for Q3 2021, reaching $10.4 million. The company executed a Master Alliance Agreement with GE Healthcare to enhance oncology initiatives, expanding its market presence. Total recurring platform customers rose to 375, with a net dollar retention rate of 137%. Despite a net loss of $21.2 million or 35 cents per share, the company anticipates full-year revenue exceeding $40 million, indicating at least 41% growth for 2021.
SOPHiA GENETICS SA (Nasdaq: SOPH) has enhanced its SOPHiA DDM Universal Whole Exome platform with the integration of Agilent's SureSelect Human All Exon v8. This new bioinformatic workflow streamlines analysis from sample to variant report, supporting both germline and cancer applications. Key features include reduced turnaround time, multiple variant detection, tailored analytics for Agilent data, and a comprehensive gene coverage. The solution aims to accelerate research in rare and inherited diseases, making data-driven medicine more accessible.